Jazz Pharmaceuticals plc (JAZZ) Investor Relations Documents

Jazz Pharmaceuticals plc (JAZZ) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-05-05. Read in-app with summaries. First-party data.

1Q26 Earnings Presentation: Jazz Pharmaceuticals reported 1Q26 revenues of $1.1 billion, up 19% YoY, and reaffirmed its 2026 financial guidance with a PDUFA date of August 25, 2026 for zanidatamab.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10Press releasePress release
2026-08-10Press releaseJazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
2026-08-03Press releasePress release
2026-08-03Press releaseJazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
2026-07-20Press releasePress release
2026-07-20Press releaseJazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
2026-06-17Press releasePress release
2026-06-17Press releaseJazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Anti
2026-06-16Press releasePress release
2026-06-16Press releaseJazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (cal
2026-06-12Press releasePress release
2026-06-12Press releaseJazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Ca
2026-06-04Press releasePress release
2026-06-04Press releaseJazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium
2026-05-27Press releasePress release
2026-05-27Press releasePhase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Ben
2026-05-12Press releasePress release
2026-05-12Press releaseJazz Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-05Earnings deck1Q26 Earnings Presentation
2026-05-05Press releasePress release
2026-05-05Press releaseJazz Pharmaceuticals Announces First Quarter 2026 Financial Results
2026-05-11PresentationCorporate Overview
2026-04-27Press releasePress release
2026-04-27Press releaseJazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziih
2026-04-21Press releasePress release
2026-04-21Press releasePress release
2026-04-21Press releaseJazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
2026-04-21Press releaseJazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroeso
2026-04-09Press releasePress release
2026-04-09Press releaseJazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodi
2026-04-01Press releasePress release
2026-04-01Press releaseJazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
2026-03-18Press releasePress release
2026-03-18Press releaseJazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
2026-02-24Press releasePress release
2026-02-24Press releaseEarnings Release
2026-02-17Press releasePress release
2026-02-17Press releaseJazz Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-02-10Press releasePress release
2026-02-10Press releaseJazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

JAZZ overview · JAZZ earnings · JAZZ financials · JAZZ KPIs · JAZZ documents · JAZZ ownership · JAZZ peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.